Factors Affecting HPV Vaccine Use Among Recent Family Medicine Residency Graduates.

Virtua Family Medicine Residency, Voorhees, NJ.
Family medicine (Impact Factor: 1.17). 02/2013; 45(2):90-4.
Source: PubMed


Many adolescents seek care by family physicians for well visits and have the opportunity for HPV vaccination during these visits. Limited information is available regarding what affects physicians in offering the vaccine. The purpose of this study was to examine factors that affect family physician administration of the HPV vaccine.
We used a mail survey of recent graduates from family medicine residencies affiliated with the South Carolina Area Health Education Consortium.
The response rate was 51.3%. Almost 79% offer the HPV vaccine at least most of the time to their adolescent female patients in their practice. Approximately 83% of respondents reported supporting the use of the HPV vaccine in males, but less than 8% reported having actually offered the vaccine to males. Those physicians who are female (OR=8.95, 95% CI=1.56--51.3), practice full time in an office setting (OR=9.08, 95% CI=1.71--48.3), are involved in teaching (OR=8.86, 95% CI=1.75--44.9), and practice in a family medicine setting (OR=8.20, 95% CI=1.69-39.8) had greater odds of offering the vaccine. Those who currently practiced in the southeastern United States were less likely to offer the vaccine (OR=0.04, 95% CI=0.002--0.59).
Recent graduates of family medicine training programs frequently offer the HPV vaccine to adolescent females. Multiple practice factors affected the odds of offering the vaccine. Though most respondents agree with using the vaccine in males, most do not offer it to males.

1 Follower
6 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: To use both quantitative and qualitative methods to investigate the evolution of practices and opinions regarding human papillomavirus (HPV) vaccination among French general practitioners. A cross-sectional study (self-questionnaires) was performed in 2007 and repeated in 2010 among 271 general practitioners. Semi-structured interviews were conducted on 27 voluntary participants by a sociologist and analyzed according to content analysis. Acceptability of HPV vaccination had increased from 2007 to 2010 (79.9 vs. 87.1 %, respectively), just as the practice of HPV vaccination among 14-year-old girls (19.0 vs. 49.1 %, respectively). Though about 60 % reported complications associated with HPV vaccination, irrespective of year, the types of difficulties have varied: difficulties related to "questions asked by patients" had decreased, though concerns about side effects had remained stable. During interviews, difficulties related to "the reason for medical consultation" and "the target age" were often associated with addressing the issue of sexuality, especially when the parents were present. Although the high level of acceptability of HPV vaccination among general practitioners, which increased from 2007 to 2010, there remain difficulties in addressing this practice.
    International Journal of Public Health 04/2014; 59(3). DOI:10.1007/s00038-014-0555-9 · 2.70 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: HPV infection leads to significant morbidity and mortality worldwide. The HPV vaccine is currently licensed and recommended for adolescents and young adults in many countries. Nonetheless, coverage levels remain low, especially in settings using a clinic-based rather than school-based delivery model. Health care professionals (HCPs) have the potential to strongly impact HPV vaccine acceptability and uptake, yet often fail to discuss and/or strongly recommend HPV vaccination. This article reviews the myriad factors that influence HPV vaccination, focusing, in particular, on those relevant to HCP communication with patients and families. It also provides a historical framework and highlights recent evidence related to HPV vaccination that may be valuable for these conversations. Lastly, it discusses strategies targeting HCPs and their practices that may increase HPV vaccination initiation and completion rates globally.
    Expert Review of Vaccines 06/2014; 13(8):1-14. DOI:10.1586/14760584.2014.933076 · 4.21 Impact Factor